A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system.

Published in: European journal of haematology (2019)

Our analysis found rates of reported breakthrough VTE were significantly higher with rivaroxaban, while apixaban had no higher than expected rates of any studied AEs.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
adverse drug
emergency department
data analysis